About TRH
Hypothalamic tripeptide (pGlu-His-Pro-NH2); binds TRH-R1/R2; stimulates TSH/prolactin release; direct CNS effects independent of thyroid axis including synaptic potentiation
Thyrotropin-releasing hormone (TRH) is a hypothalamic tripeptide that serves as the primary regulator of TSH secretion from the pituitary gland but is also widely distributed throughout the CNS as an independent neuromodulator affecting dopaminergic, cholinergic, and serotonergic neurotransmitter systems independent of its thyroid axis role. Beyond endocrine function, centrally administered TRH exerts arousal-promoting effects and has been shown in preclinical models to prevent depletion of cortical acetylcholine and monoamines following brain injury, suggesting a neuroprotective neuromodulatory role. Controlled human research has demonstrated that TRH attenuates scopolamine-induced memory impairment, consistent with its proposed role in potentiating cholinergic signaling and providing direct evidence for central cognitive effects of the parent compound. TRH is used clinically as a diagnostic agent (protirelin) for thyroid function testing; as a cognitive or neuroprotective agent it remains investigational, with no approved indication for these uses and human evidence limited to small mechanistic studies. TRH in neuroendocrinology and nootropic research Beyond its role as a hypophysiotropic releasing factor, TRH functions as a neuromodulator throughout the CNS. TRH receptors (TRH-R1 and TRH-R2) are expressed in the cerebral cortex, hippocampus, limbic system, and spinal cord, mediating effects on arousal, mood, and locomotor activity independent of the pituitary-thyroid axis. Animal studies document TRH's analeptic properties — the peptide can rapidly reverse sedation from barbiturates, ethanol, and opioids, suggesting a direct CNS excitatory role. This arousal-promoting effect has attracted research interest in fatigue, cognitive impairment, and as an emergency reversal agent in overdose contexts, though clinical translation has been limited by TRH's very short half-life (approximately 5 minutes in plasma due to rapid enzymatic degradation). Taltirelin (TA-0910), a more metabolically stable TRH analogue, is approved in Japan for spinocerebellar degeneration — the only approved clinical application in this research space. The TRH stimulation test (200–500mcg IV bolus with serial TSH/prolactin sampling) has been used diagnostically, though modern ultrasensitive TSH assays have largely replaced it. Exogenous TRH for nootropic or energy applications is available as a research peptide; intranasal delivery to bypass peripheral degradation has been explored in preclinical work.
TRH Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Compoundable
- FDA Status
- Not Evaluated
Was FDA-approved as Thypinone (NDA 017812) and Relefact TRH for diagnostic TSH testing. Both products voluntarily discontinued. On FDA 503A Category 1 bulks list for compounding. Prescription.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
7 sources cited · 7 moderate
1 RCT · 5 Cohorts · 1 Animal
Serlogical, virulence, and molecular characterization of clinical and seafood Vibrio parahaemolyticus isolates.
Microbiol Spectr · 2026
# Summary This study demonstrated that clinical isolates of *Vibrio parahaemolyticus* possessed significantly higher frequencies of virulence genes (particularly T3SS2 and T6SS1) compared to seafood isolates, with 100% of clinical strains carrying T3SS2 versus only 2.6% of seafood strains. Researchers observed that the presence of these specific virulence factors correlated with pathogenicity, suggesting that genetic profiling of these genes could serve as a marker for identifying potentially dangerous strains and support disease surveillance and prevention efforts.
Therapy-induced tumor regression heterogeneity for early prediction of response and prognosis in HER2-positive breast cancer.
BMC Med Imaging · 2026
# Summary Research found that measuring tumor regression heterogeneity (TRH)—the spatial variability within regions where tumors shrink during early treatment—on mid-treatment MRI imaging can predict pathologic complete response in HER2-positive breast cancer more accurately than conventional imaging approaches. This study demonstrated that TRH-based models achieved superior predictive performance (AUC of 0.83) and that combining TRH measurements with clinical factors further improved the ability to forecast treatment outcomes during neoadjuvant therapy.
Ribonuclease DIS3 delays aging and senescence by generating tRNA halves.
Nat Commun · 2026
# Summary Research found that the ribonuclease enzyme DIS3 generates transfer RNA halves (tRHs), which play a direct role in delaying aging and senescence across organisms from C. elegans to mammals. This study demonstrated that specific tRNA halves, particularly 5'-tRH-Gln, extend lifespan by reducing protein translation and activating longevity-associated transcription factors, revealing an evolutionarily conserved mechanism by which DIS3 counteracts aging.
Show 4 more sources ↓
Molecular Epidemiology, Antibiotic Susceptibility, and Virulence Profiling of Vibrio parahaemolyticus Isolated from Aquatic Foods in Shenzhen, China.
Foodborne Pathog Dis · 2026
# Summary Research found that among 22 *Vibrio parahaemolyticus* isolates from aquatic foods in Shenzhen, China, the virulence genes *tdh* and *trh* were both absent in all strains examined. This study demonstrated that while the isolates exhibited high antibiotic resistance and possessed type III secretion system genes, the absence of these major virulence factors suggests a different virulence profile than historically documented pandemic strains.
Microencapsulation of onion (Allium cepa L.) seed oil: influence of emulsion preparation and drying technologies.
J Microencapsul · 2026
# Summary Research found that microencapsulation of onion seed oil using a whey protein isolate combined with trehalose (WPI/TRH) wall system and spray drying achieved the highest encapsulation efficiency at 83.08%, producing smoother, more spherical particles with superior oil protection. This study demonstrated that the choice of wall material and drying method significantly influences microencapsulation effectiveness, with the WPI/TRH spray-dried formulation showing particular promise for functional food applications.
Thyrotropin releasing hormone prevents abnormalities of cortical acetylcholine and monoamines in mice following head injury
Regulatory Peptides · 1997
Research in a mouse concussion model found that pretreatment with TRH prevented both the post-injury rise in cortical acetylcholine and the reduction in norepinephrine that accompany concussion-induced disturbances of consciousness, identifying normalization of cholinergic and noradrenergic balance as a mechanism for TRH arousal and neuroprotective effects following traumatic brain injury.
TRH attenuates scopolamine-induced memory impairment in humans
Psychopharmacology · 1990
Research in a double-blind controlled clinical trial found that high-dose intravenous TRH (0.5 mg/kg) markedly attenuated scopolamine-induced impairment on a selective reminding memory task in healthy controls, providing the first human evidence for a neuromodulatory peptide effect on cholinergic cognition and a facilitatory role for TRH in human memory processes.
TRH Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy TRH — Providers & Availability
3 providersClinics
1 providerOnline Vendors
1 providerStay updated on verified TRH providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — TRH
Thyrotropin-releasing hormone (TRH) is a hypothalamic tripeptide that serves as the primary regulator of TSH secretion from the pituitary gland but is also widely distributed throughout the CNS as an independent neuromodulator affecting dopaminergic, cholinergic, and serotonergic neurotransmitter systems independent of its thyroid axis role. Beyond endocrine function, centrally administered TRH exerts arousal-promoting effects and has been shown in preclinical models to prevent depletion of cortical acetylcholine and monoamines following brain injury, suggesting a neuroprotective neuromodulatory role.
cognitive enhancement, neuroprotection, antidepressant, arousal/wakefulness.
Research on TRH primarily documents effects related to cognitive enhancement and neuroprotection and antidepressant and arousal/wakefulness. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for TRH include hyperthyroidism, cardiac arrhythmias, hypertension. 1 additional consideration are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.
3 providers in the directory currently offer TRH.
# Summary This study demonstrated that clinical isolates of *Vibrio parahaemolyticus* possessed significantly higher frequencies of virulence genes (particularly T3SS2 and T6SS1) compared to seafood isolates, with 100% of clinical strains carrying T3SS2 versus only 2.6% of seafood strains. Researchers observed that the presence of these specific virulence factors correlated with pathogenicity, suggesting that genetic profiling of these genes could serve as a marker for identifying potentially dangerous strains and support disease surveillance and prevention efforts.